

Disclaimer: This document is a translation of the original Japanese version. The original Japanese version was prepared and disclosed by the Company in accordance with Japanese accounting standards. This document does not contain or constitute any guarantee and the Company will not compensate for any losses or damages arising from interpretations or actions taken based on this document. In the case of any discrepancies between the Japanese original and this document, the Japanese original is assumed to be correct.



**FOR IMMEDIATE RELEASE: 2025/5/2**

Listed Name: M3, Inc.  
(TSE Prime Market, Ticker Code: 2413)  
(<https://corporate.m3.com/en>)  
Headquarters: Akasaka Intercity, 1-11-44 Akasaka, Minato-ku, Tokyo  
Representative: Itaru Tanimura, Representative Director  
Contact: Hirofumi Oba, Corporate Officer

**Notice Concerning Differences between Actual Non-Consolidated Results  
for the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year Ended March 31, 2024**

This notice serves to provide information regarding the difference between actual non-consolidated results for the fiscal year ended March 31, 2025 and the results for the previous fiscal year ended March 31, 2024.

**1. Differences between actual non-consolidated results for the fiscal year ended March 31, 2025 and the fiscal year ended March 31, 2024 (J-GAAP)**

	Net sales	Operating profit	Ordinary profit	Profit
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen
Actual results for the fiscal year ended March 31, 2024 (A)	51,520	23,596	84,032	75,943
Actual results for the fiscal year ended March 31, 2025 (B)	45,249	19,119	27,464	21,433
Difference (B - A)	-6,271	-4,477	-56,567	-54,510
Difference (%)	-12.2	-19.0	-67.3	-71.8

**2. Reason of differences**

Regarding the full-year non-consolidated results for the fiscal year ended March 2025, both net sales and operating profit decreased compared to the previous fiscal year. This was primarily due to a year-on-year decline in sales related to pharmaceutical marketing support, resulting from ongoing budget reductions by pharmaceutical companies and the diminishing impact of COVID-19 related projects.

Ordinary profit and profit experienced a more significant decrease compared to net sales and operating profit. This was due to the aforementioned factors, compounded by the absence of dividend income received from consolidated subsidiaries in the previous fiscal year. It is important to note that as this dividend income was from consolidated subsidiaries, there is no impact on the full-year consolidated financial results.